Vogenx, Inc.
No enriched coverage for $VOGX in the last 7 days.
No SEC Form 4 filings for $VOGX in the last 30 days.
See all $VOGX insider activity →William Wilkison reportedly owns 1.8 million shares of Vanguard Extended Duration Treasury ETF (VOGX), valued at $56.6 million. No insider trades have been filed by Wilkison in VOGX since 2021, according to SEC filings.
Vogenx, Inc. (VOGX) closed its initial public offering of 6.25 million shares at $13.00 per share, raising approximately $81.3 million before expenses. The biopharmaceutical company focuses on treatments for metabolic dysfunctions, including post-bariatric hypoglycemia and gastroparesis.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
Recent VOGX coverage spans ipo, market movers and financial news.
Large insider stake suggests confidence, may support bullish bias.
The IPO proceeds provide funding for clinical development and may support near‑term price appreciation as the stock begins trading.
Successful IPO and capital raise give the company runway for its pipeline.
The IPO could provide significant capital for R&D, potentially diluting existing shareholders but enabling clinical progress.
The IPO provides fresh capital and a public market for Vogenx, likely supporting liquidity and future financing.
AlphAI scores every news story that mentions VOGX with an AI model for sentiment and relevance, and aggregates insider trades from Vogenx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
William Wilkison reportedly owns 1.8 million shares of Vanguard Extended Duration Treasury ETF (VOGX), valued at $56.6 million. No insider trades have been filed by Wilkison in VOGX since 2021, according to SEC filings.
1 min readVogenx, Inc. (VOGX) closed its initial public offering of 6.25 million shares at $13.00 per share, raising approximately $81.3 million before expenses. The biopharmaceutical company focuses on treatments for metabolic dysfunctions, including post-bariatric hypoglycemia and gastroparesis.
1 min readEloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
3 min readVogenx, a clinical-stage biopharma, plans an IPO of 6.25M shares at $11–$13 each, aiming to raise $68M at midpoint. Funds will support mizagliflozin development and R&D. The company has no revenue and reported losses. Listing on Nasdaq under VOGX is pending SEC and exchange approval.
2 min readVogenx completed its IPO, issuing 6,250,000 shares at $13.00 each, raising $81.25M. The underwriter exercised a 15% overallotment, adding 937,500 shares and $12.19M. Total proceeds reached $93.44M before expenses, with 7,187,500 shares issued.
1 min readSeveral biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
3 min readVogenx (VOGX) rose 31.1% in pre-open trading after Amylyx Pharmaceuticals (AMLX) said it will report topline Phase 3 LUCIDITY results for avexitide on Aug. 18, 2026. Mizuho raised AMLX’s price target to $30 from $24 (Outperform). Nasdaq and S&P 500 were down, so the move was event and PBH-sector driven.
4 min readAfter-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
7 min readVogenx, Inc. (VOGX) completed an $81.3 million Nasdaq IPO, according to a JonesTrading press release. The company sold 6.25 million shares at $13.00 each, all primary shares. JonesTrading was sole book-running manager. Vogenx began trading on Aug. 12, 2026 on the Nasdaq Capital Market under VOGX, with proceeds to fund metabolic-disease therapeutics.
3 min readVogenx, a clinical-stage biopharmaceutical company, completed its initial public offering (IPO) with its common stock now trading on the Nasdaq Capital Market. The company raised $28,125,000 by selling 3,500,000 shares at $8.00 per share and granted underwriters a 45-day option to purchase additional shares. Vogenx focuses on developing therapies for metabolic diseases, with mizagliflozin as its lead product candidate.
2 min read
